Designer probiotics: a potential therapeutic for Clostridium difficile?

References

1. Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C. & Gahan, C. G. ( 2007; ). Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104, 7617–7621.[CrossRef]
   [Google Scholar]
2. Crogan, N. L. & Evans, B. C. ( 2007; ). Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 28, 161–164.[CrossRef]
   [Google Scholar]
3. Gardiner, G. E., Rea, M. C., O' Riordan, B., O' Connor, P., Morgan, S. M., Lawlor, P. G., Lynch, P. B., Cronin, M., Ross, R. P. & Hill, C. ( 2007; ). Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Appl Environ Microbiol 73, 7103–7109.[CrossRef]
   [Google Scholar]
4. Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C. & Bulpitt, C. J. ( 2007; ). Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335, 80 [CrossRef]
   [Google Scholar]
5. Kuijper, E. J., van Dissel, J. T. & Wilcox, M. H. ( 2007; ). Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 20, 376–383.
   [Google Scholar]
6. McFarland, L. V. ( 2005; ). Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 54, 101–111.[CrossRef]
   [Google Scholar]
7. Paton, A. W., Morona, R. & Paton, J. C. ( 2000; ). A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6, 265–270.[CrossRef]
   [Google Scholar]
8. Paton, A. W., Morona, R. & Paton, J. C. ( 2006; ). Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 4, 193–200.[CrossRef]
   [Google Scholar]
9. Rea, M. C., Clayton, E., O'Connor, P. M., Shanahan, F., Kiely, B., Ross, R. P. & Hill, C. ( 2007; ). Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 56, 940–946.[CrossRef]
   [Google Scholar]
10. Sheehan, V. M., Sleator, R. D., Fitzgerald, G. F. & Hill, C. ( 2006; ). Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol 72, 2170–2177.[CrossRef]
    [Google Scholar]
11. Sheehan, V. M., Sleator, R. D., Hill, C. & Fitzgerald, G. F. ( 2007; ). Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology 153, 3563–3571.[CrossRef]
    [Google Scholar]
12. Sleator, R. D. & Hill, C. ( 2006; ). Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol 17, 211–216.[CrossRef]
    [Google Scholar]
13. Sleator, R. D. & Hill, C. ( 2007a; ). Improving probiotic function using a patho-biotechnology approach. Gene Ther Mol Biol 11, 269–274.
    [Google Scholar]
14. Sleator, R. D. & Hill, C. ( 2007b; ). Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog 90, 1–14.[CrossRef]
    [Google Scholar]
15. Sleator, R. D. & Hill, C. ( 2007c; ). Probiotics as therapeutics for the developing world. J Infect Developing Countries 1, 7–12.
    [Google Scholar]
16. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. & McDonald, L. C. ( 2005; ). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079–1084.[CrossRef]
    [Google Scholar]